Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year …
…, H Amital, F Navarro-Sarabia, A Hou… - Annals of the …, 2013 - ard.bmj.com
Objective In patients with active rheumatoid arthritis (RA) despite methotrexate, to compare
the efficacy of adding tocilizumab to that of switching to tocilizumab monotherapy. Methods …
the efficacy of adding tocilizumab to that of switching to tocilizumab monotherapy. Methods …
Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene …
…, RG Trapp, KF Hobbs, M Greenwald, A Hou… - The Journal of …, 2010 - jrheum.org
Objective. To assess safety and clinical outcomes in patients with inflammatory arthritis after
intraarticular (IA) injection of rAAV2-TNFR:Fc, a recombinant adeno-associated viral vector …
intraarticular (IA) injection of rAAV2-TNFR:Fc, a recombinant adeno-associated viral vector …
A study of musculoskeletal disease in two chronic hemodialysis populations and its impact on quality of life
…, PE Prete, M Hashimzadeh, A Hou… - JCR: Journal of …, 2009 - journals.lww.com
DISCUSSION A significant number of our HD patients had the common musculoskeletal
diseases seen in an aging, general population. We did not find the HD specific complications …
diseases seen in an aging, general population. We did not find the HD specific complications …
[PDF][PDF] GENETIC HYPERCOAGULOBILITY STATE
ML Shiu, SH Barag, A Hou, S Kim - CliniCians - socalclinicians.org
Many patients with hypercoagulobility state are born with mutations of one or more genes
associated with coagulation. Common genetic mutations are Factor V Leiden, Prothrombin …
associated with coagulation. Common genetic mutations are Factor V Leiden, Prothrombin …
Sugar transporters for intercellular exchange and nutrition of pathogens
…, W Underwood, B Chaudhuri, D Chermak, G Antony… - Nature, 2010 - nature.com
Sugar efflux transporters are essential for the maintenance of animal blood glucose levels,
plant nectar production, and plant seed and pollen development. Despite broad biological …
plant nectar production, and plant seed and pollen development. Despite broad biological …
[HTML][HTML] Somatic Reversion of a Novel IL2RG Mutation Resulting in Atypical X-Linked Combined Immunodeficiency
…, T Renno, D Güngör, DA Mader, E Malenke, JS Antony… - Genes, 2021 - mdpi.com
Mutations of the IL2RG gene, which encodes for the interleukin-2 receptor common gamma
chain (γ C , CD132), can lead to X-linked severe combined immunodeficiency (X-SCID) …
chain (γ C , CD132), can lead to X-linked severe combined immunodeficiency (X-SCID) …
A mutation-agnostic hematopoietic stem cell gene therapy for metachromatic leukodystrophy
JS Antony, A Daniel-Moreno, A Lamsfus-Calle… - The CRISPR …, 2022 - liebertpub.com
Metachromatic leukodystrophy (MLD) is a rare genetic disorder caused by mutations in the
Arylsulfatase-A (ARSA) gene. The enzyme plays a key role in sulfatide metabolism in brain …
Arylsulfatase-A (ARSA) gene. The enzyme plays a key role in sulfatide metabolism in brain …
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a …
R Fleischmann, E Mysler, S Hall, AJ Kivitz, RJ Moots… - The Lancet, 2017 - thelancet.com
Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative …
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative …
[HTML][HTML] Challenges in Gene Therapy for Somatic Reverted Mosaicism in X-Linked Combined Immunodeficiency by CRISPR/Cas9 and Prime Editing
…, PG Gratz, HP Gratz, A Roig-Merino, JS Antony… - Genes, 2022 - mdpi.com
X-linked severe combined immunodeficiency (X-SCID) is a primary immunodeficiency that
is caused by mutations in the interleukin-2 receptor gamma (IL2RG) gene. Some patients …
is caused by mutations in the interleukin-2 receptor gamma (IL2RG) gene. Some patients …
Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study
IB McInnes, HY Kim, SH Lee, D Mandel… - Annals of the …, 2014 - ard.bmj.com
Objectives To evaluate the efficacy and safety of atorvastatin versus placebo in modifying
lipids in patients with rheumatoid arthritis (RA) receiving the oral Janus kinase inhibitor, …
lipids in patients with rheumatoid arthritis (RA) receiving the oral Janus kinase inhibitor, …